ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "99a02d3c-12d9-4e33-8612-0b6d8ff7b947"}, "_deposit": {"id": "26018", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "26018"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00026018", "sets": ["2091"]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-05", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "215", "bibliographicPageStart": "207", "bibliographicVolumeNumber": "80", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science"}]}]}, "item_9_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "We investigated the association between CYP2C19 genotype and additional effect of cilostazol on clopidogrel resistance (CR) in neuroendovascular therapy. Between January 2012 and January 2016, 447 consecutive patients were administered with 75-mg cilostazol/day. The VerifyNow System was used for evaluating P2Y12 reaction units (PRU) \u003e 230 and/or percentage inhibition of platelet function (% Inhibi- tion) ≤ 20 as CR. Among 158 patients with CR, 31 were administered with additional 100- or 200-mg cilostazol/day and their platelet function was evaluated. According to CYP2C19 genotypes revealed using the Spartan RX and DNeasy Blood \u0026 Tissue Kit, patients were classified into three phenotypic groups: extensive metabolizer (EM, three patients), intermediate metabolizer (IM, 12 patients), and poor metabolizer (PM, 16 patients). Administration of additional cilostazol decreased PRU (EM group: 160.7 ± 85.2 after vs 278.3 ± 40.1 before, P = 0.15; IM group: 205.6 ± 74.0 vs 254.3 ± 35.0, P = 0.02; and PM group: 227.8 ± 52.2 vs 282.1 ± 30.4, P = 0.003), and increased % Inhibition (EM group: 40.0 ± 27.9 vs 9.3 ± 3.8, P = 0.25; IM group: 31.4 ± 18.0 vs 11.8 ± 8.2, P = 0.001; and PM group: 24.6 ± 15.0 vs 10.4 ± 9.3, P = 0.001). However, the rate of normalized-clopidogrel response, thromboembolic lesions, and bleeding complications were not significantly different among the three groups. Thus, the addition of cilostazol was effective on CR in terms of PRU, % Inhibition, rate of change of normalized-clopidogrel response, thromboembolic events, and bleeding complications irrespective of phenotype. ", "subitem_description_type": "Abstract"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.80.2.207", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University Graduate School of Medicine, School of Medicine"}]}, "item_9_relation_43": {"attribute_name": "異版である", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/802.html ", "subitem_relation_type_select": "URI"}}]}, "item_9_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_7": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Tajima, Hayato"}], "nameIdentifiers": [{"nameIdentifier": "77282", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Izumi, Takashi"}], "nameIdentifiers": [{"nameIdentifier": "77283", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyachi, Shigeru"}], "nameIdentifiers": [{"nameIdentifier": "77284", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsubara, Noriaki"}], "nameIdentifiers": [{"nameIdentifier": "77285", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ito, Masashi"}], "nameIdentifiers": [{"nameIdentifier": "77286", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Imai, Tasuku"}], "nameIdentifiers": [{"nameIdentifier": "77287", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishihori, Masahiro"}], "nameIdentifiers": [{"nameIdentifier": "77288", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shintai, Kazunori"}], "nameIdentifiers": [{"nameIdentifier": "77289", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Okamoto, Sho"}], "nameIdentifiers": [{"nameIdentifier": "77290", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Araki, Yoshio"}], "nameIdentifiers": [{"nameIdentifier": "77291", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kumakura, Yasuo"}], "nameIdentifiers": [{"nameIdentifier": "77292", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Furukawa-Hibi, Yoko"}], "nameIdentifiers": [{"nameIdentifier": "77293", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamada, Kiyofumi"}], "nameIdentifiers": [{"nameIdentifier": "77294", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Wakabayashi, Toshihiko"}], "nameIdentifiers": [{"nameIdentifier": "77295", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-05-28"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "07_Tajima.pdf", "filesize": [{"value": "415.6 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 415600.0, "url": {"label": "07_Tajima.pdf", "url": "https://nagoya.repo.nii.ac.jp/record/26018/files/07_Tajima.pdf"}, "version_id": "771e8640-0830-4c87-8b40-f526188bcf12"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "CYP2C19 genotype", "subitem_subject_scheme": "Other"}, {"subitem_subject": "cilostazol", "subitem_subject_scheme": "Other"}, {"subitem_subject": "clopidogrel resistance", "subitem_subject_scheme": "Other"}, {"subitem_subject": "endovascular treatment", "subitem_subject_scheme": "Other"}, {"subitem_subject": "VerifyNow System", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy"}]}, "item_type_id": "9", "owner": "1", "path": ["2091"], "permalink_uri": "https://doi.org/10.18999/nagjms.80.2.207", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-05-28"}, "publish_date": "2018-05-28", "publish_status": "0", "recid": "26018", "relation": {}, "relation_version_is_last": true, "title": ["Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy"], "weko_shared_id": 3}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 80(2)

Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy

https://doi.org/10.18999/nagjms.80.2.207
https://doi.org/10.18999/nagjms.80.2.207
6fca4e3d-fdfd-4b3b-8005-e0e1a21b4dda
名前 / ファイル ライセンス アクション
07_Tajima.pdf 07_Tajima.pdf (415.6 kB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2018-05-28
タイトル
タイトル Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy
著者 Tajima, Hayato

× Tajima, Hayato

WEKO 77282

Tajima, Hayato

Search repository
Izumi, Takashi

× Izumi, Takashi

WEKO 77283

Izumi, Takashi

Search repository
Miyachi, Shigeru

× Miyachi, Shigeru

WEKO 77284

Miyachi, Shigeru

Search repository
Matsubara, Noriaki

× Matsubara, Noriaki

WEKO 77285

Matsubara, Noriaki

Search repository
Ito, Masashi

× Ito, Masashi

WEKO 77286

Ito, Masashi

Search repository
Imai, Tasuku

× Imai, Tasuku

WEKO 77287

Imai, Tasuku

Search repository
Nishihori, Masahiro

× Nishihori, Masahiro

WEKO 77288

Nishihori, Masahiro

Search repository
Shintai, Kazunori

× Shintai, Kazunori

WEKO 77289

Shintai, Kazunori

Search repository
Okamoto, Sho

× Okamoto, Sho

WEKO 77290

Okamoto, Sho

Search repository
Araki, Yoshio

× Araki, Yoshio

WEKO 77291

Araki, Yoshio

Search repository
Kumakura, Yasuo

× Kumakura, Yasuo

WEKO 77292

Kumakura, Yasuo

Search repository
Furukawa-Hibi, Yoko

× Furukawa-Hibi, Yoko

WEKO 77293

Furukawa-Hibi, Yoko

Search repository
Yamada, Kiyofumi

× Yamada, Kiyofumi

WEKO 77294

Yamada, Kiyofumi

Search repository
Wakabayashi, Toshihiko

× Wakabayashi, Toshihiko

WEKO 77295

Wakabayashi, Toshihiko

Search repository
キーワード
主題Scheme Other
主題 CYP2C19 genotype
キーワード
主題Scheme Other
主題 cilostazol
キーワード
主題Scheme Other
主題 clopidogrel resistance
キーワード
主題Scheme Other
主題 endovascular treatment
キーワード
主題Scheme Other
主題 VerifyNow System
抄録
内容記述 We investigated the association between CYP2C19 genotype and additional effect of cilostazol on clopidogrel resistance (CR) in neuroendovascular therapy. Between January 2012 and January 2016, 447 consecutive patients were administered with 75-mg cilostazol/day. The VerifyNow System was used for evaluating P2Y12 reaction units (PRU) > 230 and/or percentage inhibition of platelet function (% Inhibi- tion) ≤ 20 as CR. Among 158 patients with CR, 31 were administered with additional 100- or 200-mg cilostazol/day and their platelet function was evaluated. According to CYP2C19 genotypes revealed using the Spartan RX and DNeasy Blood & Tissue Kit, patients were classified into three phenotypic groups: extensive metabolizer (EM, three patients), intermediate metabolizer (IM, 12 patients), and poor metabolizer (PM, 16 patients). Administration of additional cilostazol decreased PRU (EM group: 160.7 ± 85.2 after vs 278.3 ± 40.1 before, P = 0.15; IM group: 205.6 ± 74.0 vs 254.3 ± 35.0, P = 0.02; and PM group: 227.8 ± 52.2 vs 282.1 ± 30.4, P = 0.003), and increased % Inhibition (EM group: 40.0 ± 27.9 vs 9.3 ± 3.8, P = 0.25; IM group: 31.4 ± 18.0 vs 11.8 ± 8.2, P = 0.001; and PM group: 24.6 ± 15.0 vs 10.4 ± 9.3, P = 0.001). However, the rate of normalized-clopidogrel response, thromboembolic lesions, and bleeding complications were not significantly different among the three groups. Thus, the addition of cilostazol was effective on CR in terms of PRU, % Inhibition, rate of change of normalized-clopidogrel response, thromboembolic events, and bleeding complications irrespective of phenotype.
内容記述タイプ Abstract
出版者
出版者 Nagoya University Graduate School of Medicine, School of Medicine
言語
言語 eng
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
ID登録
ID登録 10.18999/nagjms.80.2.207
ID登録タイプ JaLC
関連情報
関連タイプ isVersionOf
識別子タイプ URI
関連識別子 http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/802.html
ISSN(print)
収録物識別子タイプ ISSN
収録物識別子 0027-7622
書誌情報 Nagoya Journal of Medical Science

巻 80, 号 2, p. 207-215, 発行日 2018-05
著者版フラグ
値 publisher
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 12:49:19.031793
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3